7月 2026
- 首頁
- iDEXIS Compounding
iDEXIS Compounding(包含公司地區)
查看更多網站流量與參與度資訊- idexis.co.za
iDEXIS Compounding的熱門網域總造訪量
了解iDEXIS Compounding市場觸達率與潛在市場影響力。
過去 3 個月的訪問總量
子公司細目
iDEXIS Compounding的熱門網域平均造訪時長
分析iDEXIS Compounding參與度指標。
過去 3 個月平均造訪時長
子公司細目
iDEXIS Compounding的熱門網域平均頁面瀏覽量
了解iDEXIS Compounding如何保持使用者的參與度、培養其興趣,並鼓勵他們採取下一步。
過去 3 個月平均頁面瀏覽量
子公司細目
想要取得更深入的流量洞見?
篩選超過 2,030 萬家線上企業。在流量激增、開始或停止使用技術或獲得正面評價時,發現新的潛在客戶。
新聞與訊號來自iDEXIS Compounding
透過 Similarweb 銷售訊號提醒,每當目標受眾出現新的機會或威脅時,你就會收到每日更新的已識別購買訊號。
新聞Novo Nordisk A/S filed suit against Idexis on Jun 1st '26.The warning follows a High Court interim order granted last month barring iDexis from manufacturing and selling medicines containing semaglutide, in a case brought by Novo Nordisk.
7月 13, 2026閱讀更多
新聞Idexis had issues with illegally manufacturing and selling unregistered semaglutide products and competing in South Africa's fast-growing weight-loss market without complying with medicines regulations on Jun 1st '26.The Danish drugmaker argued that iDexis was illegally manufacturing and selling unregistered semaglutide products and competing in South Africa's fast-growing weight-loss market without complying with medicines regulations.
7月 9, 2026閱讀更多
新聞Idexis had issues with producing unauthorized copies of semaglutide on Jun 10th '26.Novo Nordisk has on Wednesday sued the South African pharmacy Idexis in court for producing unauthorized copies of semaglutide.
6月 10, 2026閱讀更多
查看所有iDEXIS Compounding信號
讓銷售團隊專注於最有希望的機會。透過安排機會的優先順序,並在正確的時間參與,您可將工作最佳化,並完成更多交易。
